ULTRA-TECHNEKOW V4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ULTRA-TECHNEKOW V4 (ULTRA-TECHNEKOW V4).
ULTRA-TECHNEKOW V4 is a radiopharmaceutical containing sodium pertechnetate Tc-99m. Technetium-99m is a gamma-emitting radionuclide that localizes in specific tissues due to its physical and chemical properties. In the brain, it crosses the blood-brain barrier only in areas with disrupted integrity (e.g., tumors, infarcts). In the thyroid, it is trapped similarly to iodide but not organified. It is secreted into the gastric mucosa and excreted via the renal system. Its distribution allows for scintigraphic imaging of various organs.
| Metabolism | Technetium-99m is not metabolized; it remains as pertechnetate ion until physical decay to technetium-99 (half-life ~6 hours). Excretion is primarily renal via glomerular filtration, with some gastrointestinal secretion. |
| Excretion | Primarily renal excretion: 90-95% of the administered technetium-99m is excreted unchanged via glomerular filtration within 24 hours. Less than 5% is eliminated via fecal route. |
| Half-life | Physical half-life of technetium-99m is 6.02 hours; biological half-life is approximately 24 hours, resulting in effective half-life of 5.2 hours. Clinical imaging is typically performed within 30 minutes to 4 hours post-injection. |
| Protein binding | Negligible protein binding (<5%). Primarily bound to albumin. |
| Volume of Distribution | Vd = 0.5-0.8 L/kg, indicating distribution into extracellular fluid and total body water, with minimal intracellular penetration. |
| Bioavailability | Intravenous: 100% bioavailable. Not administered orally. |
| Onset of Action | Intravenous: Localization in target organs begins within minutes; optimal imaging time is 30-60 minutes for most studies (e.g., bone, cardiac). |
| Duration of Action | Activity sufficient for imaging persists for 4-6 hours post-injection. By 24 hours, less than 5% of initial activity remains. |
Intravenous administration of 5-30 mCi (185-1110 MBq) for imaging, as a single dose.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required; however, caution in severe renal impairment due to potential altered biodistribution. |
| Liver impairment | No specific dose adjustment recommended; however, monitor for altered clearance in severe hepatic impairment. |
| Pediatric use | Weight-based: 0.05-0.15 mCi/kg (1.85-5.55 MBq/kg) intravenously; minimum dose 1 mCi (37 MBq). |
| Geriatric use | No specific dose adjustment; use lowest effective dose based on clinical status and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ULTRA-TECHNEKOW V4 (ULTRA-TECHNEKOW V4).
| Breastfeeding | Tc-99m pertechnetate is excreted in breast milk; M/P ratio not established. Interrupt breastfeeding for 24-48 hours after administration. Discard milk during this period. |
| Teratogenic Risk | Technetium-99m pertechnetate crosses the placenta. First trimester: risk of fetal thyroid ablation due to iodine uptake; avoid unless essential. Second/third trimester: fetal radiation exposure; use only if benefit outweighs risk. No known structural teratogenicity. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Absolute: Known hypersensitivity to any component of the product","Relative: Pregnancy (unless benefit outweighs risk); lactation; recent administration of other iodinated contrast media or medications affecting thyroid uptake (e.g., amiodarone) which may reduce image quality"]
| Precautions | ["Hypersensitivity/anaphylactoid reactions: Rare but risk","Radiation exposure: Must justify benefit vs. cumulative radiation dose; use minimal activity for adequate imaging","Breastfeeding: Interrupt for at least 24 hours after administration","Pregnancy: Consider alternatives unless imaging is essential (fetal radiation exposure)","Children: Adjust dose based on weight and minimize activity","Thyroid uptake: Ensure patient is not taking medications that interfere with uptake (e.g., thyroid hormones, antithyroid drugs, perchlorate); perform image promptly after injection","Radiopharmaceutical should be used within specified time after preparation (elution) to avoid excessive free pertechnetate"] |
Loading safety data…
| Monitor maternal vital signs during and after injection. Fetal radiation dose assessment via dosimetry if administration is necessary. Ensure adequate maternal hydration to promote radionuclide excretion. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies not available; theoretical risk from radiation to gonads considered minimal at diagnostic doses. |